340 related articles for article (PubMed ID: 12039923)
1. Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines.
Disis ML; Gooley TA; Rinn K; Davis D; Piepkorn M; Cheever MA; Knutson KL; Schiffman K
J Clin Oncol; 2002 Jun; 20(11):2624-32. PubMed ID: 12039923
[TBL] [Abstract][Full Text] [Related]
2. Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine.
Disis ML; Grabstein KH; Sleath PR; Cheever MA
Clin Cancer Res; 1999 Jun; 5(6):1289-97. PubMed ID: 10389911
[TBL] [Abstract][Full Text] [Related]
3. Effect of dose on immune response in patients vaccinated with an her-2/neu intracellular domain protein--based vaccine.
Disis ML; Schiffman K; Guthrie K; Salazar LG; Knutson KL; Goodell V; dela Rosa C; Cheever MA
J Clin Oncol; 2004 May; 22(10):1916-25. PubMed ID: 15143085
[TBL] [Abstract][Full Text] [Related]
4. Immunization of cancer patients with a HER-2/neu, HLA-A2 peptide, p369-377, results in short-lived peptide-specific immunity.
Knutson KL; Schiffman K; Cheever MA; Disis ML
Clin Cancer Res; 2002 May; 8(5):1014-8. PubMed ID: 12006513
[TBL] [Abstract][Full Text] [Related]
5. Delayed-type hypersensitivity response is a predictor of peripheral blood T-cell immunity after HER-2/neu peptide immunization.
Disis ML; Schiffman K; Gooley TA; McNeel DG; Rinn K; Knutson KL
Clin Cancer Res; 2000 Apr; 6(4):1347-50. PubMed ID: 10778962
[TBL] [Abstract][Full Text] [Related]
6. Immunization of cancer patients with HER-2/neu-derived peptides demonstrating high-affinity binding to multiple class II alleles.
Salazar LG; Fikes J; Southwood S; Ishioka G; Knutson KL; Gooley TA; Schiffman K; Disis ML
Clin Cancer Res; 2003 Nov; 9(15):5559-65. PubMed ID: 14654536
[TBL] [Abstract][Full Text] [Related]
7. Toxicity, immunogenicity, and induction of E75-specific tumor-lytic CTLs by HER-2 peptide E75 (369-377) combined with granulocyte macrophage colony-stimulating factor in HLA-A2+ patients with metastatic breast and ovarian cancer.
Murray JL; Gillogly ME; Przepiorka D; Brewer H; Ibrahim NK; Booser DJ; Hortobagyi GN; Kudelka AP; Grabstein KH; Cheever MA; Ioannides CG
Clin Cancer Res; 2002 Nov; 8(11):3407-18. PubMed ID: 12429628
[TBL] [Abstract][Full Text] [Related]
8. Tumor antigen-specific T-cell expansion is greatly facilitated by in vivo priming.
Dang Y; Knutson KL; Goodell V; dela Rosa C; Salazar LG; Higgins D; Childs J; Disis ML
Clin Cancer Res; 2007 Mar; 13(6):1883-91. PubMed ID: 17363545
[TBL] [Abstract][Full Text] [Related]
9. Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients.
Knutson KL; Schiffman K; Disis ML
J Clin Invest; 2001 Feb; 107(4):477-84. PubMed ID: 11181647
[TBL] [Abstract][Full Text] [Related]
10. Results of the first phase I clinical trial of the novel II-key hybrid preventive HER-2/neu peptide (AE37) vaccine.
Holmes JP; Benavides LC; Gates JD; Carmichael MG; Hueman MT; Mittendorf EA; Murray JL; Amin A; Craig D; von Hofe E; Ponniah S; Peoples GE
J Clin Oncol; 2008 Jul; 26(20):3426-33. PubMed ID: 18612158
[TBL] [Abstract][Full Text] [Related]
11. Vaccination with human HER-2/neu (435-443) CTL peptide induces effective antitumor immunity against HER-2/neu-expressing tumor cells in vivo.
Gritzapis AD; Mahaira LG; Perez SA; Cacoullos NT; Papamichail M; Baxevanis CN
Cancer Res; 2006 May; 66(10):5452-60. PubMed ID: 16707474
[TBL] [Abstract][Full Text] [Related]
12. Flt3 ligand as a vaccine adjuvant in association with HER-2/neu peptide-based vaccines in patients with HER-2/neu-overexpressing cancers.
Disis ML; Rinn K; Knutson KL; Davis D; Caron D; dela Rosa C; Schiffman K
Blood; 2002 Apr; 99(8):2845-50. PubMed ID: 11929774
[TBL] [Abstract][Full Text] [Related]
13. Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes.
Brossart P; Stuhler G; Flad T; Stevanovic S; Rammensee HG; Kanz L; Brugger W
Cancer Res; 1998 Feb; 58(4):732-6. PubMed ID: 9485028
[TBL] [Abstract][Full Text] [Related]
14. Results from a phase I clinical study of the novel Ii-Key/HER-2/neu(776-790) hybrid peptide vaccine in patients with prostate cancer.
Perez SA; Kallinteris NL; Bisias S; Tzonis PK; Georgakopoulou K; Varla-Leftherioti M; Papamichail M; Thanos A; von Hofe E; Baxevanis CN
Clin Cancer Res; 2010 Jul; 16(13):3495-506. PubMed ID: 20466887
[TBL] [Abstract][Full Text] [Related]
15. Peptide-based, but not whole protein, vaccines elicit immunity to HER-2/neu, oncogenic self-protein.
Disis ML; Gralow JR; Bernhard H; Hand SL; Rubin WD; Cheever MA
J Immunol; 1996 May; 156(9):3151-8. PubMed ID: 8617935
[TBL] [Abstract][Full Text] [Related]
16. Humoral epitope-spreading following immunization with a HER-2/neu peptide based vaccine in cancer patients.
Disis ML; Goodell V; Schiffman K; Knutson KL
J Clin Immunol; 2004 Sep; 24(5):571-8. PubMed ID: 15359116
[TBL] [Abstract][Full Text] [Related]
17. Treatment with autologous antigen-presenting cells activated with the HER-2 based antigen Lapuleucel-T: results of a phase I study in immunologic and clinical activity in HER-2 overexpressing breast cancer.
Park JW; Melisko ME; Esserman LJ; Jones LA; Wollan JB; Sims R
J Clin Oncol; 2007 Aug; 25(24):3680-7. PubMed ID: 17704416
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the HER2/neu-derived peptide GP2 for use in a peptide-based breast cancer vaccine trial.
Mittendorf EA; Storrer CE; Foley RJ; Harris K; Jama Y; Shriver CD; Ponniah S; Peoples GE
Cancer; 2006 Jun; 106(11):2309-17. PubMed ID: 16596621
[TBL] [Abstract][Full Text] [Related]
19. Pre-existent immunity to the HER-2/neu oncogenic protein in patients with HER-2/neu overexpressing breast and ovarian cancer.
Disis ML; Knutson KL; Schiffman K; Rinn K; McNeel DG
Breast Cancer Res Treat; 2000 Aug; 62(3):245-52. PubMed ID: 11072789
[TBL] [Abstract][Full Text] [Related]
20. Cancer vaccines targeting the HER2/neu oncogenic protein.
Disis ML; Schiffman K
Semin Oncol; 2001 Dec; 28(6 Suppl 18):12-20. PubMed ID: 11774201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]